France Units July Deadline for Medical Hashish Rules as Withheld Examine Reveals Opioid Reductions

France’s well being minister has confirmed to Agence France-Presse (AFP) that the delayed regulatory texts wanted to push via its incoming generalised medical hashish market shall be revealed subsequent month (July 2026). 

The dedication from French authorities follows the pressured launch of outcomes from France’s long-running medical hashish experiment, which confirmed that therapy was efficient in lowering opioid and analgesic use throughout 4 indications. 

U.CANNABIS, which tracked practically 2000 sufferers earlier than and after receiving therapy, was accomplished in September 2025, however was by no means made out there to the general public. 

Now,  due to a proper request to the Fee d’accès aux paperwork administratifs (CADA) by French hashish affiliation l’Union des industriels pour la valorisation des extraits de chanvre (UIVEC), the figures have been revealed. 

Ludovic Rachou, President of UIVEC, stated in a press launch to members: “The scientific knowledge is stacking up and converging. It’s French, it’s public, it’s strong. We’re asking the federal government to publish the texts earlier than the top of June 2026. Sufferers in therapeutic deadlock have waited lengthy sufficient.”

France’s medical hashish limbo

France’s medical hashish pilot programme, launched in 2021, was initially supposed as a two-year proof of idea forward of a generalised nationwide framework. 5 years on, that framework has but to be enacted. Dogged by political inaction, the pilot has been repeatedly prolonged, with taking part sufferers dropping from a peak of three,000 to round 700.

A extra steady political atmosphere modified the calculus. The 2024 Social Safety Finance Act made generalisation a authorized obligation, and by early 2026 the ultimate regulatory steps have been in lastly movement. 

At Hashish Europa Paris in February, officers from the Route Générale de la Santé and the Route de la Sécurité Sociale offered the draft decree setting out how cannabis-based medicines can be evaluated and priced beneath France’s social safety framework.

That decree stays unpublished. Till it’s, HAS can’t ship a proper reimbursement opinion; with out that opinion, firms can’t register merchandise with ANSM, and generalised prescribing can’t start. July’s anticipated affirmation will mark the beginning of this closing course of. 

READ MORE…

U.CANNABIS Examine

The publication of the information from the U.CANNABIS research was a essential think about securing a timeline dedication from the French well being minister. Solely after reviewing the outcomes was AFP prompted to hunt a direct response on when the laws can be revealed. 

Nonetheless, the discharge of the outcomes themselves can also be a major improvement. The U.CANNABIS was commissioned immediately by ANSM, France’s medicines regulator, because the official scientific analysis of the nation’s medical hashish experimentation programme. 

It was carried out independently by Inserm UMR 1219 and the AHeaD epidemiology crew on the Université de Bordeaux.

Researchers have been instructed to trace what occurred to sufferers’ healthcare consumption within the twelve months earlier than and the six months after they began medical hashish therapy. 

Not like many real-world research, these weren’t self-reported outcomes, however have been based mostly on reimbursement knowledge. The analysis crew cross-referenced the ReCann medical registry, which data each affected person enrolled within the experimentation, towards the SNDS, France’s nationwide social safety reimbursement database. 

The research was finalised in September 2025, however remained sealed till UIVEC’s CADA request, 9 months later. Towards the present backdrop of delayed deliberations on how medical hashish ought to be reimbursed, figures monitoring sufferers’ interplay with healthcare extra broadly symbolize a essential issue within the equasion. 

What the research discovered

The research, seen by Enterprise of Hashish, coated 1,971 sufferers throughout the 5 accredited indications. As an observational research utilizing interrupted time sequence methodology, it might determine modifications in healthcare use related to hashish initiation, nevertheless it can’t precisely set up causation in the way in which a randomised managed trial would. 

Readers wishing to entry the total doc ought to contact UIVEC immediately.

The authors concluded that medical hashish initiation reveals ‘a constructive influence, albeit of low depth, on healthcare use.’ The outcomes are statistically important throughout most indications, however the impact sizes are modest. 

The clearest sign comes from refractory neuropathic ache, the most important cohort at 1,105 sufferers. The share receiving analgesics fell by roughly 4 in each 100 after initiation, from round 73% to 69%. 

Gabapentinoid use dropped by round three per 100, robust opioid use by 1.4 per 100, and benzodiazepine use by 1.6 per 100. Month-to-month attendances at specialist power ache day hospitals fell by round 0.9 per 100 per 30 days.  

Palliative care reveals the most important absolute numbers, with roughly 21 in each 100 sufferers fewer on robust opioids after initiation, and common day by day opioid doses declining by 13.6 outlined day by day doses per affected person. 

The research notes, nonetheless, that analgesic use on this group was already declining within the months earlier than medical hashish initiation, complicating direct attribution. 

In oncology, round 12 in each 100 sufferers fewer obtained analgesics after initiation. Amongst sufferers with MS spasticity, the frequency of non-opioid analgesic use fell by about six in each 100, however the research’s dose evaluation confirmed a rise in analgesic amount after initiation, a sample the authors attribute to modelling artefacts within the segmented regression fairly than a real enhance in treatment burden. 

In refractory epilepsy, benzodiazepine reductions have been noticed however didn’t attain statistical significance, with the authors citing inadequate pattern measurement.

5 therapy strains, one medication

Taken collectively, the neuropathic ache knowledge alone reveals reductions throughout 5 separate therapy strains, gabapentinoids, non-opioid analgesics, benzodiazepines, robust opioids, and specialist ache clinic visits.

For HAS, which should decide whether or not cannabis-based medicines displace current therapies or complement them, that may be a extra helpful sign than affected person self-report. The SNDS methodology, monitoring precise reimbursement claims, is the precise sort of proof the reimbursement analysis is designed to weigh.

The outcomes sit alongside a security file the reimbursement argument may also require. ANSM pharmacovigilance monitoring throughout the total experimentation has recorded zero circumstances of dependancy or misuse. The latest monitoring interval logged 30 pharmacovigilance circumstances, eight critical, primarily neurological and psychiatric hostile occasions, and none involving dependency.

If the decree is revealed on the brand new timeline, clears Conseil d’État overview, and HAS delivers its reimbursement opinion in autumn as anticipated, the primary prescriptions beneath the generalised framework are unlikely to return earlier than 2027.